Fig. 3

Gut microbiota from YYFZBJS volunteers delay the progression of intestinal tumorigenesis. a Design of stool gavage experiment to Apc^Min/+ mice. Mice were treatmented with Abx from week 6, and sacrificed at week 22 (n = 8). b Display of the fecal extracts of the Apc^Min/+ mice with FMT treatment for 12 weeks. c Left: typical adenomatous polyp seen in infected Apc^Min/+ mice showing high-grade dysplasia and carcinoma in situ. Right: minute polyp with remnant dysplastic glands close to the surface epithelium. Blue arrows indicated adenocarcinoma cell. Magnification bars, 100 μM. Histological analysis of intestinal tumors applyed in the two FMT group mice (n = 8 for each group). d The tumor size distribution in the intestine was listed and compared with control-FMT (n = 8 for each group). Data shown represent means ± SD. *P < 0.05 vs. control-FMT. e Immunohistochemical staining with an antibody against PCNA and Ki67 in control-FMT group and YYFZBJS-FMT treatment group. Magnification bars, 100 μM. Data are given as means ± SD of 8 animals per experimental group, with Welch’s correction, one-tailed t-test. *P < 0.05 vs. control-FMT. f Electron microscopy in the lumen infiltration of control-FMT group mice and YYFZBJS-FMT mice at age of week 22. Both microvilli and goblet cells can also be seen. The black arrow refers to the intestinal microvilli; The red arrow indicates a tight connection. Magnification bars, 500 nM. g Fecal bacterial DNA was prepared from Control-FMT group and YYFZBJS-FMT treatment group. Relative genus abundance was shown as percentage of each OTU in the total OTUs (n = 5/group). Data shown represent means ± SD. *P < 0.05